Loading...
News 2018-04-27T13:47:37+00:00

News

Number Title Author Date
27
Alteogen Inc. obtained IND approval for a clinical trial in Korea for Eylea Biosimilar (ALT-L9)
alteogen | 2019.05.22 | Votes 0 | Views 171
alteogen 2019.05.22
26
Alteogen applies for P1 trial for Eylea biosimilar
alteogen | 2019.02.28 | Votes 0 | Views 182
alteogen 2019.02.28
25
Alteogen Inc. Becomes First Mover for Eylea Biosimilar with securing global competitiveness by registering patent
alteogen | 2019.01.04 | Votes 0 | Views 237
alteogen 2019.01.04
24
Alteogen and Lynkogen Expand Agreement to Include Additional Proprietary Fusion Proteins Targeting NASH
alteogen | 2018.12.04 | Votes 0 | Views 161
alteogen 2018.12.04
23
Alteogen's Kadcyla biobetter gains edge in gastric cancer with FDA orphan designation
alteogen | 2018.08.17 | Votes 0 | Views 182
alteogen 2018.08.17
22
Alteogen Gets FDA Approval for Orphan Drug Designation with an Antibody-Drug Conjugate for Gastric Cancer
alteogen | 2018.08.07 | Votes 0 | Views 156
alteogen 2018.08.07
21
Alteogen develops antibody transferring IV to SC injection
alteogen | 2018.07.30 | Votes 0 | Views 159
alteogen 2018.07.30
20
Alteogen, Lynkogen targeting large NASH, diabetes markets in cross-royalty collaboration
alteogen | 2018.07.11 | Votes 0 | Views 136
alteogen 2018.07.11
19
Alteogen and Lynkogen Enter into an Exclusive Option Agreement
alteogen | 2018.07.04 | Votes 0 | Views 146
alteogen 2018.07.04
18
18 January 2018 Bio & Medicine Alteogen to seek US approval for clinical trials of Eylea biosimilar
alteogen | 2018.05.28 | Votes 0 | Views 181
alteogen 2018.05.28